Response to Comments: Allogeneic Hematopoietic Cell Transplantation (HCT) for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin

This document is a response to comments concerning allogeneic hematopoietic cell transplantation (HCT) for primary refractory or relapsed Hodgkin and non-Hodgkin lymphomas of B-cell or T-cell origin. The provided excerpt identifies the indication but does not include specific coverage criteria, exclusions, documentation requirements, or frequency limits; review of the full policy is required to determine detailed coverage rules.

"Allogeneic hematopoietic cell transplantation (HCT) for primary refractory or relapsed Hodgkin lymphoma or non-Hodgkin lymphoma of B-cell or T-cell origin."

Sign up to see full coverage criteria, indications, and limitations.